Kalaris Therapeutics Inc (KLRS)

$4.40 -0.07 (-1.57%)
Market Cap 104.69M
Revenue (ttm) 0.00
Net Income (ttm) -43.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 50,500
Avg Vol 88,970
Day's Range N/A - N/A
Shares Out 23.79M
Stochastic %K 57%
Beta 0.15
Analysts Strong Sell
Price Target $17.86

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeuti...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-249-2727
Address:
400 Connell Drive, Suite 5500 Berkeley Heights, Berkeley Heights, United States
Orlandotrader
Orlandotrader Jun. 24 at 3:32 PM
$KLRS Kalaris also confirms that its Phase 1b/2 multiple ascending dose study of TH103 for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients. The company remains on-track to share initial data from the study in 1H 2027 which is designed to accelerate TH103's clinical development and inform dose selection for potential future Phase 3 development. Dead money till 2027
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:28 PM
$KLRS saw its shareholders elect three new directors and ratify its auditor at the 2026 annual meeting.
0 · Reply
Orlandotrader
Orlandotrader May. 27 at 1:24 PM
$KLRS Actually a Fund Purchase of Million Four where a Director of Kalaris has voting power. I’ll Take it.
0 · Reply
YouVSYou
YouVSYou May. 26 at 2:01 AM
💰 Top Insider Buys AHs 🔹 $KLRS — Director loaded 244,300 shares at $4.83~$1.18M buy. Biggest size on the board. 🔹 $TWFG — Director bought 33,283 shares at $18.64~$620K insider scoop. 🔹 $MKTW — 10% owner Frank Stansberry added 20,100 shares at $17.21~$346K conviction buy. 🔹 $AAT — Executive Chairman grabbed 10,000 shares at $22.67~$226K direct confidence. 🔹 $CRT — 10% owner added 18,902 shares at $10.87~$205K insider buy.
0 · Reply
BecauseOfScout
BecauseOfScout Apr. 30 at 6:53 PM
$KLRS Notice of EFFECT filed 2 weeks ago — $10 warrants are now active. Expecting investors to start buying these cheap shares. Starter position.
0 · Reply
notreload_ai
notreload_ai Apr. 16 at 3:53 PM
$KLRS gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients. https://notreload.xyz/xy/morgan-stanley-sees-big-potential-in-kalaris-eye-drug-th103/
0 · Reply
Quantumup
Quantumup Apr. 16 at 1:10 PM
Morgan Stanley🏁 $KLRS and said: We initiate coverage of KLRS with an Overweight rating and a $14 price target. $EYPT $OCUL REGN RHHBY Here's what else Morgan Stanley had to say in its initiation report: https://x.com/Quantumup1/status/2044764520149651643?s=20
0 · Reply
focafoca99
focafoca99 Apr. 11 at 8:58 PM
$KLRS said CFO Matthew Gall will step down on April 14, with chief accounting officer Brett Hagen taking over as principal financial officer.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 7 at 2:02 AM
$KLRS
0 · Reply
ApolloAlerts
ApolloAlerts Mar. 19 at 10:15 PM
$KLRS
0 · Reply
Latest News on KLRS
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Jun 23, 2026, 8:00 AM EDT - 2 days ago

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics initiated with a Buy at TD Cowen

2026-06-15T10:10:28.000Z - 10 days ago

Kalaris Therapeutics initiated with a Buy at TD Cowen

Kalaris to Present at Clinical Trials at the Summit 2026

Jun 12, 2026, 8:00 AM EDT - 13 days ago

Kalaris to Present at Clinical Trials at the Summit 2026

Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform

2026-05-14T17:28:58.000Z - 5 weeks ago

Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform

Kalaris Therapeutics initiated with an Outperform at Wedbush

2026-05-14T11:10:47.000Z - 6 weeks ago

Kalaris Therapeutics initiated with an Outperform at Wedbush

Kalaris Therapeutics price target lowered to $25 from $26 at Citizens

2026-05-13T09:56:28.000Z - 6 weeks ago

Kalaris Therapeutics price target lowered to $25 from $26 at Citizens

Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)

2026-05-12T16:14:07.000Z - 6 weeks ago

Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Kalaris Therapeutics Earnings release: Q1 2026

Kalaris Therapeutics Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Kalaris Therapeutics Quarterly report: Q1 2026

Kalaris Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Kalaris Therapeutics Proxy statement: Proxy filing

Kalaris Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Kalaris Therapeutics Proxy statement: Proxy filing

Kalaris Therapeutics initiated with an Overweight at Morgan Stanley

2026-04-16T08:55:11.000Z - 2 months ago

Kalaris Therapeutics initiated with an Overweight at Morgan Stanley

Kalaris Therapeutics Registration statement: Registration filing

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Kalaris Therapeutics Registration statement: Registration filing

Kalaris Therapeutics Registration statement: Registration filing

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Kalaris Therapeutics Registration statement: Registration filing

Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)

2026-03-17T12:05:43.000Z - 3 months ago

Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)

Kalaris Therapeutics sees cash runway into 4Q27

2026-03-17T12:05:29.000Z - 3 months ago

Kalaris Therapeutics sees cash runway into 4Q27

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:00 AM EDT - 3 months ago

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Annual report: Q4 2025

Mar 17, 2026, 8:00 AM EDT - 3 months ago

Kalaris Therapeutics Annual report: Q4 2025

Kalaris Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 8:00 AM EDT - 3 months ago

Kalaris Therapeutics Earnings release: Q4 2025

Kalaris Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Kalaris Therapeutics Slides: Corporate presentation

Kalaris Therapeutics initiated with a Buy at Chardan

2025-12-23T09:35:14.000Z - 6 months ago

Kalaris Therapeutics initiated with a Buy at Chardan

Kalaris Therapeutics price target raised to $26 from $20 at Citizens

2025-12-18T10:51:00.000Z - 6 months ago

Kalaris Therapeutics price target raised to $26 from $20 at Citizens

Kalaris Therapeutics announces $50M private placement

2025-12-17T23:05:37.000Z - 6 months ago

Kalaris Therapeutics announces $50M private placement

Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27

2025-12-17T23:05:28.000Z - 6 months ago

Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Dec 17, 2025, 5:59 PM EST - 6 months ago

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics announces initial data from TH103 trial

2025-12-17T21:15:58.000Z - 6 months ago

Kalaris Therapeutics announces initial data from TH103 trial

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Dec 17, 2025, 4:01 PM EST - 6 months ago

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 24, 2025, 8:00 AM EST - 7 months ago

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)

2025-11-12T13:05:33.000Z - 8 months ago

Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 12, 2025, 8:00 AM EST - 8 months ago

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Kalaris Therapeutics Quarterly report: Q3 2025

Kalaris Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Kalaris Therapeutics Earnings release: Q3 2025

Kalaris Therapeutics appoints Gall as Chief Financial Officer

2025-11-03T12:41:20.000Z - 8 months ago

Kalaris Therapeutics appoints Gall as Chief Financial Officer

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Nov 3, 2025, 7:30 AM EST - 8 months ago

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Kalaris Therapeutics initiated with an Outperform at Citizens JMP

2025-11-03T09:50:12.000Z - 8 months ago

Kalaris Therapeutics initiated with an Outperform at Citizens JMP

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 3:26 PM EDT - 10 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103

2025-09-15T12:16:03.000Z - 10 months ago

Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics initiated with a Strong Buy at Raymond James

2025-09-02T20:35:24.000Z - 10 months ago

Kalaris Therapeutics initiated with a Strong Buy at Raymond James

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Kalaris Therapeutics Quarterly report: Q2 2025

Kalaris Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Kalaris Therapeutics Earnings release: Q2 2025

Kalaris Therapeutics Proxy statement: Proxy Filing

Jul 1, 2025, 8:00 AM EDT - 1 year ago

Kalaris Therapeutics Proxy statement: Proxy Filing

Kalaris Therapeutics Proxy statement: Proxy Filing

Jul 1, 2025, 8:00 AM EDT - 1 year ago

Kalaris Therapeutics Proxy statement: Proxy Filing

Kalaris Therapeutics Slides: Investor Presentation

Jun 17, 2025, 4:30 PM EDT - 1 year ago

Kalaris Therapeutics Slides: Investor Presentation

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

May 23, 2025, 11:03 AM EDT - 1 year ago

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 8:00 AM EDT - 1 year ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Kalaris Therapeutics Quarterly report: Q1 2025

Kalaris Therapeutics Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Kalaris Therapeutics Earnings release: Q1 2025

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir

Mar 18, 2025, 4:21 PM EDT - 1 year ago

Kalaris Announces Closing of Merger with AlloVir

ALVR

Orlandotrader
Orlandotrader Jun. 24 at 3:32 PM
$KLRS Kalaris also confirms that its Phase 1b/2 multiple ascending dose study of TH103 for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients. The company remains on-track to share initial data from the study in 1H 2027 which is designed to accelerate TH103's clinical development and inform dose selection for potential future Phase 3 development. Dead money till 2027
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:28 PM
$KLRS saw its shareholders elect three new directors and ratify its auditor at the 2026 annual meeting.
0 · Reply
Orlandotrader
Orlandotrader May. 27 at 1:24 PM
$KLRS Actually a Fund Purchase of Million Four where a Director of Kalaris has voting power. I’ll Take it.
0 · Reply
YouVSYou
YouVSYou May. 26 at 2:01 AM
💰 Top Insider Buys AHs 🔹 $KLRS — Director loaded 244,300 shares at $4.83~$1.18M buy. Biggest size on the board. 🔹 $TWFG — Director bought 33,283 shares at $18.64~$620K insider scoop. 🔹 $MKTW — 10% owner Frank Stansberry added 20,100 shares at $17.21~$346K conviction buy. 🔹 $AAT — Executive Chairman grabbed 10,000 shares at $22.67~$226K direct confidence. 🔹 $CRT — 10% owner added 18,902 shares at $10.87~$205K insider buy.
0 · Reply
BecauseOfScout
BecauseOfScout Apr. 30 at 6:53 PM
$KLRS Notice of EFFECT filed 2 weeks ago — $10 warrants are now active. Expecting investors to start buying these cheap shares. Starter position.
0 · Reply
notreload_ai
notreload_ai Apr. 16 at 3:53 PM
$KLRS gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients. https://notreload.xyz/xy/morgan-stanley-sees-big-potential-in-kalaris-eye-drug-th103/
0 · Reply
Quantumup
Quantumup Apr. 16 at 1:10 PM
Morgan Stanley🏁 $KLRS and said: We initiate coverage of KLRS with an Overweight rating and a $14 price target. $EYPT $OCUL REGN RHHBY Here's what else Morgan Stanley had to say in its initiation report: https://x.com/Quantumup1/status/2044764520149651643?s=20
0 · Reply
focafoca99
focafoca99 Apr. 11 at 8:58 PM
$KLRS said CFO Matthew Gall will step down on April 14, with chief accounting officer Brett Hagen taking over as principal financial officer.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 7 at 2:02 AM
$KLRS
0 · Reply
ApolloAlerts
ApolloAlerts Mar. 19 at 10:15 PM
$KLRS
0 · Reply
Orlandotrader
Orlandotrader Mar. 3 at 6:12 PM
$KLRS Come to PaPa
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 24 at 8:07 PM
$KLRS Current Stock Price: $10.76
0 · Reply
char13
char13 Feb. 19 at 10:21 AM
$KLRS more than 100m market cap and a director bot a massive stake recently
0 · Reply
WallStArb
WallStArb Jan. 2 at 3:21 PM
$KLRS broke down under support - next data 12 - 18 months out
2 · Reply
WallStArb
WallStArb Dec. 29 at 4:18 PM
$KLRS looking for 3.50 - 4.20
0 · Reply
WallStArb
WallStArb Dec. 29 at 3:07 PM
$KLRS expect this to trade back down near net cash out 90d - this never had a PIPE when they did the reverse so I expect the $50M essentially covers that now - curious why the investors didn’t do the pipe prior to the data - now it’s a 12 month wait for next major data points
0 · Reply
ZenithZulu
ZenithZulu Dec. 25 at 2:57 PM
$KLRS Forward returns depend heavily on whether management can deliver consistent operational results. Execution gaps should narrow meaningfully over coming quarters. Visible traction across segments would strengthen the thesis. The next phase will be defined less by vision and more by delivery.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 9:43 AM
$KLRS
0 · Reply